SINGLE-AGENT TREATMENT OF ADVANCED SEMINOMA WITH CARBOPLATIN IN OUTPATIENTS

Abstract

Six patients with advanced seminoma (stage IIc) received single-agent carboplatin therapy. The drug was administered to outpatients without prior hyperhydration. All five patients who completed the regimen of three to four cycles achieved complete remission, which was confirmed histologically in four patients by retroperitoneal lymph node dissection. No severe dose-effects were observed. Single-agent carboplatin therapy is a highly efficient regimen with very little toxicity. This treatment seems to be the therapy of choice in patients with advanced seminoma.